XPHYTO THERAPEUTICS RECEIVES GERMAN CANNABIS LICENCE FOR SCIENTIFIC CULTIVATION AND EXTRACTION
Vancouver, Canada (July 24, 2019) - XPhyto Therapeutics Corp. (“XPhyto” or the “Company”) is pleased to announce that the German Federal Institute for Drugs and Medical Devices (“BfArM”) has granted XPhyto’s wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH (“Bunker”), a cannabis cultivation and extraction licence for scientific purposes (the “Licence”). Subject to meeting BfArM security requirements, the Licence is valid and authorizes the Company to cultivate and extract up to 70 different strains of Cannabis sativa and indica for scientific purposes at Bunker’s high-security facility located in a monitored security area in the south of Germany (Bavaria).“XPhyto’s German cannabis cultivation and extraction licence is a unique opportunity for our European operations. With a focus on Canada and Germany, we are building an industry leading medical cannabis company focused on pharmaceutical-grade quality and scientific validation,” said Hugh Rogers, CEO of XPhyto.
“Germany is emerging as the largest legal medical cannabis market in the world and we expect it to grow to be a multi-billion dollar industry within five years. XPhyto is well positioned as a first-mover in this exciting market,” noted Robert Barth, VP European Corporate Development of XPhyto and Managing Director of Bunker.
XPhyto has filed a final prospectus with the British Columbia Securities Commission and has applied to list on the Canadian Securities Exchange (“CSE”). Subject to final listing approval, the Company expects to trade on the CSE in the next 30 days. XPhyto has reserved the CSE trading symbol “XPHY”.
For further information, please contact:
Hugh Rogers
CEO & Director
+1.780.818.6422
Robert Barth
VP European Corporate Development
+49 8331 99481 11
info@xphyto.com
www.xphyto.com
XPhyto Therapeutics Corp.
Legal Address
Suite 1500 – 1055 W Georgia Street / Vancouver, BC V6E 4N7 / Canada
Corporate Office Address
Suite 270 – 1820 Fir Street / Vancouver, BC V6J 3B1 / Canada
Contact
Canada / Phone: +1-780-818-6422 / Mail info@xphyto.com
Germany / Phone: +49 8331 99481 10 / Mail info@xphyto.com
About XPhyto Therapeutics Corp.
XPhyto is a science-focused cannabis company developing analytical testing, processing, and formulation capability in Canada and research, cultivation, extraction, import, distribution, and manufacturing in Germany. Two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified analytical testing capability, as well as extraction, isolation, and formulation facilities, and drug research and development expertise. XPhyto acquired 100% ownership of the German cannabis company Bunker Pflanzenextrakte GmbH, which has been granted a cannabis cultivation and extraction licence for scientific purposes by BfArM, the German Federal Institute for Drugs and Medical Devices.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release XPHYTO THERAPEUTICS RECEIVES GERMAN CANNABIS LICENCE FOR SCIENTIFIC CULTIVATION AND EXTRACTION here
News-ID: 1854499 • Views: …
More Releases for XPhyto
Investigation for Long-Term Investors in shares of PharmaCielo Ltd. (OTC: PCLOF) …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of PharmaCielo Ltd..
Investors who are current long term investors in PharmaCielo Ltd. (OTC: PCLOF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in OTC: PCLOF stocks follows a lawsuit filed against PharmaCielo Ltd. over…
Deadline in Lawsuit on May 5th coming up for Investors in PharmaCielo Ltd. (OTC: …
A deadline is coming up on May 5, 2020 in the lawsuit filed for certain investors of PharmaCielo Ltd. (OTC: PCLOF) over alleged securities laws violations by PharmaCielo Ltd.
Investors who purchased shares of PharmaCielo Ltd. (OTC: PCLOF) have certain options and there are strict and short deadlines running. Deadline: HHHHH. OTC: PCLOF stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed…
Lawsuit filed for Investors in shares of PharmaCielo Ltd. (OTC: PCLOF)
An investor, who purchased shares of PharmaCielo Ltd. (OTC: PCLOF), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by PharmaCielo Ltd..
Investors who purchased shares of PharmaCielo Ltd. (OTC: PCLOF) have certain options and for certain investors are short and strict deadlines running. Deadline: May 5, 2020. OTC: PCLOF investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On March 2, 2020,…